drugset / Trial / NCT04148781

Fampridine-SR and Optic Neuritis Recovery

NCT04148781

Phase 0 Unknown 20 enrolled Courtney Casserly
NaSingle-groupOpen-labelTreatment

Summary

Optic Neuritis (ON) is a condition that occurs in approximately 50% of individuals with relapse remitting MS, and is the presenting event in 15-20% of patients who go on to develop MS. These ON events present with a decline in vision over several days with painful eye movements. The purpose of this study is to collect pilot data on the effect of Fampridine-SR on the recovery of visual function after demyelinating optic neuritis.Our team evaluated a person with ON who had incomplete recovery which was quite bothersome to her. After a one-month treatment course Fampridine SR,her visual functioning improved. Based on this case, we present a unique opportunity to evaluate the potential benefit of Fampridine-SR as a potential treatment for persons who do not fully recover from acute ON.

Timeline

Start
2022-03-22
Primary completion
2023-12
Completion
2024-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Dalfampridine Small molecule 10 mg Oral

Indications